Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACHROMYCIN vs ARESTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.
Minocycline is a semisynthetic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the elongating peptide chain. This action is bacteriostatic. In periodontal disease, it also inhibits matrix metalloproteinases (MMPs), particularly collagenase, and suppresses inflammatory cytokine production, reducing tissue destruction.
Infections caused by susceptible strains of bacteria (e.g., Mycoplasma pneumoniae, Chlamydia trachomatis, Rickettsia species),Acne vulgaris,Periodontitis (as adjunctive therapy),Off-label: Chronic obstructive pulmonary disease exacerbations, malaria prophylaxis
Adjunctive treatment of periodontitis (subgingival administration by a dental professional),Off-label: Treatment of acne vulgaris, rosacea, rheumatoid arthritis (MRSA decolonization is not standard)
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
1 mg subgingival application per periodontal pocket, applied as a single dose by a dental professional.
6-12 hours; prolonged to 48-72 hours in severe renal impairment
The terminal elimination half-life of minocycline is 11-17 hours (mean ~16 hours). This long half-life allows for twice-daily dosing in systemic use, but for Arestin (subgingival), local sustained release provides prolonged local exposure.
Primarily renally excreted unchanged; minimal hepatic metabolism.
Minocycline is extensively metabolized in the liver via multiple pathways, with at least 6 metabolites identified. The major metabolic routes include hydroxylation at the 9-position (via CYP450 enzymes, possibly CYP3A4) and N-demethylation. It also undergoes glucuronidation. The drug has a long half-life (11–17 hours) and undergoes enterohepatic recirculation.
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Minocycline is primarily eliminated via hepatic metabolism and biliary/fecal excretion. Renal excretion accounts for approximately 10-20% of the dose, with the remainder excreted in feces via bile. Less than 10% is recovered unchanged in urine.
50-60% bound to serum proteins
Minocycline is approximately 70-75% bound to plasma proteins.
1.5-2.0 L/kg; indicates extensive tissue penetration
Volume of distribution for minocycline is 1.0-1.3 L/kg, indicating extensive tissue penetration, consistent with its lipophilic nature and ability to concentrate in various tissues including gingival crevicular fluid.
Oral: 75-80%; Topical: minimal systemic absorption
Subgingival administration: Direct local delivery results in negligible systemic absorption (bioavailability <1% relative to oral dose). Oral minocycline bioavailability is approximately 90-100%.
GFR 50-80 m L/min: no adjustment; GFR 10-50 m L/min: administer every 12-24 hours; GFR <10 m L/min: administer every 24 hours or avoid.
No dose adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No dose adjustment required for hepatic impairment.
25-50 mg/kg/day orally divided every 6 hours; maximum 2 g/day.
Not recommended in pediatric patients below 18 years of age due to lack of safety and efficacy data.
Initiate at lower end of dosing range due to age-related renal function decline; monitor renal function.
No specific dose adjustment; use with caution due to potential age-related comorbidities.
No FDA boxed warning
None.
Photosensitivity reactions,Esophageal ulceration if taken with insufficient fluids,Pseudotumor cerebri in adults,Pancreatitis,Hepatotoxicity,Renal impairment (accumulation may worsen renal function),Superinfection with resistant organisms
Photosensitivity: May cause exaggerated sunburn; avoid prolonged sun exposure.,Superinfection: Use may result in overgrowth of nonsusceptible organisms, including fungi.,Hepatotoxicity: Rare cases of liver injury; discontinue if symptoms occur.,Renal impairment: Use with caution in renal dysfunction; may accumulate.,Autoimmune syndromes: Cases of drug-induced lupus, serum sickness-like reactions, and vasculitis reported.,Intracranial hypertension: Associated with minocycline; symptoms include headache and blurred vision.,Tooth discoloration: May cause permanent discoloration of teeth in children under 8 years.,Bone development: Use during pregnancy may affect fetal skeletal development.
Hypersensitivity to tetracyclines,Pregnancy (second and third trimesters) due to fetal harm,Children under 8 years due to permanent tooth discoloration and enamel hypoplasia,Severe hepatic or renal impairment
Hypersensitivity to any tetracycline antibiotic.,Pregnancy (especially second and third trimesters) – risk of fetal harm.,Lactation – excreted in breast milk, potential for adverse effects in nursing infants.,Children under 8 years of age – risk of permanent tooth discoloration.
Avoid dairy products (milk, cheese, yogurt) within 2-3 hours of taking Achromycin, as calcium binds tetracycline and reduces absorption. Also avoid iron-fortified foods, calcium-fortified juices, and high-calcium meals. Take on an empty stomach with a full glass of water; food, especially dairy, decreases absorption by up to 50%.
No known food interactions. Patients should avoid hard, crunchy, or sticky foods for at least 7 days after application to prevent mechanical disruption of the microspheres.
ACHROMYCIN (tetracycline) is classified as FDA Pregnancy Category D. First trimester: Associated with minor malformations, but risk is low. Second and third trimesters: Exposure can cause permanent discoloration of deciduous teeth (yellow-gray-brown) due to deposition during calcification, and reversible inhibition of bone growth. Avoid use after the fourth month of pregnancy. Risk of maternal hepatotoxicity if used intravenously in pregnancy.
ARESTIN (minocycline hydrochloride) is a tetracycline antibiotic. Class D: Positive evidence of human fetal risk. Use contraindicated in pregnancy. Risk is highest in second and third trimesters due to tetracycline deposition in fetal bones and teeth, causing permanent discoloration and enamel hypoplasia. Potential for reversible inhibition of bone growth. First trimester exposure may be associated with neural tube defects and cardiac malformations, though data are limited.
Tetracycline is excreted into breast milk in low concentrations. Theoretical risk of dental discoloration and bone growth suppression in nursing infants, but levels are usually below therapeutic. M/P ratio is approximately 0.5-0.8. Use with caution, especially in infants with prolonged exposure. American Academy of Pediatrics considers tetracyclines compatible with breastfeeding.
Minocycline is excreted into human breast milk with an M/P ratio of approximately 0.6 to 0.8. Theoretical risk of permanent tooth discoloration and bone growth inhibition in nursing infants. Avoid use in breastfeeding women; if necessary, consider temporary cessation of breastfeeding. Alternative antibiotics are preferred.
No dosage adjustment is recommended for pregnancy; however, use is contraindicated after the first trimester due to risks to the fetus. If essential, use the lowest effective dose for the shortest duration. Intravenous doses should be cautious due to risk of hepatotoxicity; reduce dose in renal impairment.
Pregnancy is a contraindication; ARESTIN should not be used. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may reduce minocycline levels, but no dose adjustments are recommended because the drug is contraindicated. No studies establish safe dosing in pregnancy.
Achromycin (tetracycline) should be administered on an empty stomach (1 hour before or 2 hours after meals) to ensure adequate absorption. Avoid concurrent use with dairy products, antacids, iron, calcium, magnesium, or bismuth subsalicylate as they chelate tetracycline and reduce absorption. Tetracycline can cause photosensitivity; advise patients to avoid prolonged sun exposure and use sunscreen. It is contraindicated in pregnancy (risk of hepatotoxicity and fetal bone/teeth discoloration), lactation, and children under 8 years (permanent tooth discoloration and bone growth inhibition). Monitor for signs of superinfection, especially Clostridium difficile-associated diarrhea. Tetracycline may increase the effect of warfarin; monitor INR closely.
ARESTIN (minocycline microspheres) is a locally administered antibiotic adjunct to scaling and root planing (SRP) for periodontitis. Do not use in patients with known hypersensitivity to tetracyclines. Avoid placement in areas with active abscesses. Apply only into periodontal pockets ≥5 mm. Do not pack deeply; overfill may cause tissue irritation. No systemic antibiotic effect; monitor for local adverse effects like pain or swelling.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Do not take with dairy products, antacids, iron supplements, or calcium supplements; separate by at least 2-3 hours.,Avoid excessive sunlight or tanning beds; use sunscreen and wear protective clothing to prevent severe sunburn.,Complete the full course of treatment even if you feel better; do not skip doses.,Notify your doctor immediately if you develop watery or bloody diarrhea, rash, headache, blurred vision, or signs of infection worsening.,Do not use if you are pregnant, planning to become pregnant, or breastfeeding; this medication can harm the unborn baby or nursing infant.,Keep out of reach of children; expired tetracycline can cause kidney damage.
Do not brush, floss, or use interdental cleaners in the treated area for 7 days after application.,Avoid eating hard, crunchy, or sticky foods for 1 week to prevent dislodging the microspheres.,Some minor discomfort, redness, or swelling at the application site is normal and usually resolves within days.,Report severe pain, swelling, or signs of infection (e.g., pus, fever) to your dentist promptly.,Continue routine oral hygiene in untreated areas as directed by your dentist.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACHROMYCIN vs ARESTIN, answered by our medical review team.
ACHROMYCIN is a Tetracycline Antibiotic that works by Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.. ARESTIN is a Tetracycline Antibiotic that works by Minocycline is a semisynthetic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the elongating peptide chain. This action is bacteriostatic. In periodontal disease, it also inhibits matrix metalloproteinases (MMPs), particularly collagenase, and suppresses inflammatory cytokine production, reducing tissue destruction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACHROMYCIN and ARESTIN depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACHROMYCIN is: 250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.. The standard adult dose of ARESTIN is: 1 mg subgingival application per periodontal pocket, applied as a single dose by a dental professional.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACHROMYCIN and ARESTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACHROMYCIN is classified as Category C. ACHROMYCIN (tetracycline) is classified as FDA Pregnancy Category D. First trimester: Associated with minor malformations, but risk is low. Second and third trimesters: Exposure ca. ARESTIN is classified as Category C. ARESTIN (minocycline hydrochloride) is a tetracycline antibiotic. Class D: Positive evidence of human fetal risk. Use contraindicated in pregnancy. Risk is highest in second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.